A blood‐based multi‐pathway biomarker assay for early detection and staging of Alzheimer's disease across ethnic groups

• DOI: 10.1002/alz.13676
• Publication Date: 2024-01-06T14:33:34Z
• Authors: Yuanbing Jiang; Hyebin Uhm; Fanny C. Ip; Li Ouyang; Ronnie M. N. Lo; Elaine Y. L. Cheng; Xiaoyun Cao; Clara M. C. Tan; Brian C. H. Law; Paula Ortiz‐Romero; Albert Puig‐Pijoan; Aida Fernández‐Le...; José Contador; Kin Y. Mok; John Hardy; Timothy C. Y. Kwok; Vincent C. T. Mok; Marc Suárez‐Calvet; Henrik Zetterberg; Amy K. Y. Fu; Nancy Y. Ip
• Keywords: Multiplex; Biomarker Discovery; Tau protein; Endophenotype

Abstract INTRODUCTION Existing blood‐based biomarkers for Alzheimer's disease (AD) mainly focus on its pathological features. However, studies associated with other biological processes a comprehensive evaluation of AD status are limited. METHODS We developed blood‐based, multiplex biomarker assay that measures the levels 21 proteins involved in multiple pathways. evaluated assay's performance classifying and indicating AD‐related endophenotypes three independent cohorts from Chinese or European‐descent populations. RESULTS The 21‐protein accurately classified (area under receiver operating characteristic curve [AUC] = 0.9407 to 0.9867) mild cognitive impairment (MCI; AUC 0.8434 0.8945) while also brain amyloid pathology. Moreover, simultaneously changes five individuals revealed ethnic‐specific dysregulations upon progression. DISCUSSION This study demonstrated utility multi‐pathway early screening staging AD, providing insights patient stratification precision medicine. Highlights authors disease. classifies AD/MCI indicates can assess activities processes. Ethnic‐specific were revealed.